Hostname: page-component-89b8bd64d-j4x9h Total loading time: 0 Render date: 2026-05-09T09:32:34.515Z Has data issue: false hasContentIssue false
  • English
  • Français

The Prevalence and Incidence of Dementia Due to Alzheimer’s Disease: a Systematic Review and Meta-Analysis

Published online by Cambridge University Press:  16 June 2016

Kirsten M. Fiest ,
Jodie I. Roberts ,
Colleen J. Maxwell ,
David B. Hogan ,
Eric E. Smith ,
Alexandra Frolkis ,
Adrienne Cohen ,
Andrew Kirk ,
Dawn Pearson  and
Tamara Pringsheim
...Show all authors
Kirsten M. Fiest
Affiliation:
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada O’Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada
Jodie I. Roberts
Affiliation:
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada O’Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada
Colleen J. Maxwell
Affiliation:
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada Schools of Pharmacy and Public Health and Health Systems, University of Waterloo, Waterloo, Ontario, Canada Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
David B. Hogan
Affiliation:
Brenda Strafford Chair in Geriatric Medicine, University of Calgary, Calgary, Alberta, Canada Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
Eric E. Smith
Affiliation:
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
Alexandra Frolkis
Affiliation:
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
Adrienne Cohen
Affiliation:
Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
Andrew Kirk
Affiliation:
Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Dawn Pearson
Affiliation:
Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada
Tamara Pringsheim
Affiliation:
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada O’Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada
Nathalie Jetté*
Affiliation:
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada O’Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada
*
Correspondence to: Nathalie Jetté, Foothills Medical Center, Department of Clinical Neurosciences, 1403-29th Street NW, Calgary, Alberta T2N 4N1, Canada. Email: Nathalie.jette@albertahealthservices.ca.
Rights & Permissions [Opens in a new window]

Abstract

Background

Updated information on the epidemiology of dementia due to Alzheimer’s disease (AD) is needed to ensure that adequate resources are available to meet current and future healthcare needs. We conducted a systematic review and meta-analysis of the incidence and prevalence of AD.

Methods

The MEDLINE and EMBASE databases were searched from 1985 to 2012, as well as the reference lists of selected articles. Included articles had to provide an original population-based estimate for the incidence and/or prevalence of AD. Two individuals independently performed abstract and full-text reviews, data extraction and quality assessments. Random-effects models were employed to generate pooled estimates stratified by age, sex, diagnostic criteria, location (i.e., continent) and time (i.e., when the study was done).

Results

Of 16,066 abstracts screened, 707 articles were selected for full-text review. A total of 119 studies met the inclusion criteria. In community settings, the overall point prevalence of dementia due to AD among individuals 60+ was 40.2 per 1000 persons (CI95%: 29.1-55.6), and pooled annual period prevalence was 30.4 per 1000 persons (CI95%: 15.6-59.1). In community settings, the overall pooled annual incidence proportion of dementia due to AD among individuals 60+ was 34.1 per 1000 persons (CI95%: 16.4-70.9), and the incidence rate was 15.8 per 1000 person-years (CI95%: 12.9-19.4). Estimates varied significantly with age, diagnostic criteria used and location (i.e., continent).

Conclusions

The burden of AD dementia is substantial. Significant gaps in our understanding of its epidemiology were identified, even in a high-income country such as Canada. Future studies should assess the impact of using such newer clinical diagnostic criteria for AD dementia such as those of the National Institute on Aging–Alzheimer’s Association and/or incorporate validated biomarkers to confirm the presence of Alzheimer pathology to produce more precise estimates of the global burden of AD.

Résumé

Prévalence et incidence de la démence due à la maladie d’Alzheimer : revue systématique et méta-analyse. Contexte: Nous avons besoin d’informations sur l’épidémiologie de la démence due à la maladie d’Alzheimer (MA) afin de nous assurer que des ressources adéquates sont disponibles pour satisfaire les besoins actuels et futurs de la population en soins de santé. Nous avons effectué une revue systématique et une méta-analyse de l’incidence et de la prévalence de la MA. Méthodologie: Nous avons effectué une recherche dans les bases de données MEDLINE et EMBASE de 1985 à 2012 ainsi que dans la liste de références d’articles retenus. Les articles retenus devaient fournir des estimations de l’incidence et/ou de la prévalence populationnelle de la MA. Deux évaluateurs ont revu indépendamment les résumés et le texte intégral ainsi que l’extraction des données des publications et en ont évalué la qualité. Nous avons utilisé des modèles à effets aléatoires pour générer des estimations regroupées stratifiées par âge, sexe, critères diagnostiques, lieu (continent) et temps (moment où l’étude a été réalisée). Résultats: Parmi les 16 066 résumés examinés, 707 articles ont été retenus pour une revue du texte intégral. En tout, 119 études rencontraient les critères d’inclusion. Dans la communauté, la prévalence ponctuelle globale de la démence due à la MA chez les individus de 60 ans et plus était de 40,2 par 1 000 (IC à 95%: 29,1 à 55,6) et la prévalence annuelle pour les données regroupées était de 30,4 par 1 000 (IC à 95%: 15,6 à 59,1). Dans la communauté, la proportion d’incidence annuelle globale regroupée de la démence due à la MA chez les individus de 60 ans et plus était de 34,1 par 1 000 (IC à 95%: 16,4 à 70,9) et le taux d’incidence était de 15,8 par 1 000 personnes-années (IC à 95%: 12,9 à 19,4). Les estimations variaient significativement selon l’âge, les critères diagnostiques utilisés et le lieu (continent). Conclusions: Le fardeau de la démence dû à la MA est considérable. Nous avons identifié des lacunes importantes dans notre compréhension de son épidémiologie, même dans un pays à revenu élevé comme le Canada. Des études ultérieures devraient évaluer l’impact de l’utilisation de critères diagnostiques plus récents pour identifier la démence due à la MA tels ceux du National Institute on Aging-Alzheimer’s Association et/ou incorporer des biomarqueurs validés pour confirmer la présence de la pathologie de la MA et fournir des estimations plus précises de son fardeau global.

Keywords

Alzheimer’sdementiameta-analysissystematic review

Information

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 43 , Supplement S1: The Epidemiology of Dementia and its Commoner Neurodegenerative Causes Systematic Reviews and Meta-Analyses of the Incidence and Prevalence of Dementia, Alzheimer’s Disease, Dementia with Lewy Bodies and Frontotemporal Dementia , April 2016 , pp. S51 - S82
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an open access article, distributed under the terms of the creative commons attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © The Canadian Journal of Neurological Sciences Inc. 2016

Introduction

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder leading to cognitive impairment, neuropsychiatric symptoms, disability, dependency, caregiver burden, substantial healthcare expenditures and premature death.Reference Demakis 1 - 3 Up to 70% of the dementias occurring in older adults are attributed in whole or in part to AD.Reference Brookmeyer, Evans, Hebert, Langa, Heeringa and Plassman 4 Though described more than a century ago,Reference Alzheimer 5 treatment options remain limited. Available pharmacotherapies provide modest symptomatic benefitsReference Doody, Stevens, Beck, Dubinsky, Kaye and Gwyther 6 of debatable cost-effectiveness.Reference Morris 7

Updated information on the epidemiology of dementia due to AD is needed if we are to ensure that adequate resources are mobilized to deal with the needs of those with this condition and their families. Such studies can also inform prevention strategies and approaches to management. Systematic reviews on the epidemiology of dementia generally do not deal with specific causes such as AD, but rather provide estimates of overall dementia. 8 , 9 The last systematic review of the global incidence of dementia specifically due to AD was published in 2008.Reference Ziegler-Graham, Brookmeyer, Johnson and Arrighi 10 While the age-specific incidence rate of AD dementia doubles approximately every 5.5 years in older populationsReference Kukull, Higdon, Bowen, McCormick, Teri and Schellenberg 11 and several studies have produced estimates stratified by sex and geographic region,Reference Ziegler-Graham, Brookmeyer, Johnson and Arrighi 10 , Reference Jorm and Jolley 12 - Reference Rockwood and Stadnyk 14 an unexplored issue is the heterogeneity produced by differing diagnostic criteria and study setting. In a majority of the more recent reviews, either a systematic methodology was not utilizedReference Ziegler-Graham, Brookmeyer, Johnson and Arrighi 10 , Reference Jorm and Jolley 12 , Reference Fratiglioni, De Ronchi and Aguero-Torres 15 or it was uncertain whether one was.Reference Rockwood and Stadnyk 14 , Reference Clarfield 16 , Reference Suh and Shah 17

In this report, we present an updated systematic review and meta-analysis of population-based studies of the incidence and prevalence of dementia due to AD. We also examine the extent and causes of heterogeneity in these estimates.

Methods

This is one in a series of systematic reviews on the prevalence and incidence of priority neurological conditions as part of the National Population Health Study of Neurological Conditions.Reference Caesar-Chavannes and MacDonald 18

Search Strategy

The systematic review and meta-analysis were conducted according to a predetermined protocol based on the PRISMA statement for systematic reviews and meta-analyses.Reference Moher, Liberati, Tetzlaff and Altman 19 The search strategy (Appendix A) was developed by the study authors (who have expertise in dementia and/or disease epidemiology) in consultation with a research librarian with systematic review expertise. The primary search was conducted in the MEDLINE and EMBASE databases in February of 2011 and updated in July of 2012. References were exported and managed using EndNote X5. 20 International studies published before the year 2000 and Canadian studies published prior to 1985 were excluded because of the availability of prior meta-analyses summarizing earlier work. The earlier date for Canadian studies was to ensure that all relevant national work was included, as this was part of a nationally funded study examining the burden of neurological conditions in Canada. The review was restricted to articles published in English or French. The reference lists of included articles were manually searched for additional articles.

Study Selection

Two reviewers independently examined the titles and abstracts of all retrieved references in order to identify papers likely reporting original population-based data on the prevalence and/or incidence of AD dementia. Two reviewers also independently examined the full-text papers identified during the first phase. To be included in the systematic review, reviewed papers had to: (1) report original research; (2) be population-based; and (3) provide an incidence and/or prevalence estimate of dementia due to AD. Disagreements about the inclusion of articles were resolved by consensus or involvement of a third author if necessary.

Data Extraction and Study Quality

Two reviewers extracted data from included articles using a standard data collection form. Any disagreement was resolved by consensus. When multiple articles reported data on the same study population, the most accurate and comprehensive data as determined by the reviewers were used. In cases where the studies reported on different data collection years or subgroups (e.g., by sex and/or age), all data were included. The demographic data recorded included age, sex, setting (community-only, both community and institution, institution-only) and study location (i.e., Africa, Asia, Australia, Europe, North America, South America). The approach to ascertain cases was noted, as were sources of data and definitions/diagnostic criteria used. Incidence and prevalence estimates of AD dementia from each study were recorded, along with any stratification by age, sex or year of data collection. The quality of the included studies was evaluated using an assessment toolReference Loney, Chambers, Bennett, Roberts and Stratford 21 , Reference Boyle 22 (Appendix B), with each study given a quality score that ranged from 0 to 8 (higher scores indicating a higher-quality assessment).

Data Synthesis and Analysis

The significance of age, sex, diagnostic criteria, location (i.e., continent) and time (i.e., when the study was conducted) on incidence and prevalence estimates was assessed using meta-regression. Age was examined using the youngest-aged person in the study as a continuous factor of potential heterogeneity (note that few studies provided data on mean or median age). Sex, diagnostic criteria and geographic location were treated as categorical variables. Changes over time were examined using the study start, midpoint and end-years as potential sources of heterogeneity. All pooled estimates were restricted to studies reporting on older individuals (i.e., aged 60+, 65+, 70+) to mitigate the potential confounding effects of age. All period estimates were converted to annual estimates (e.g., period prevalence represents the annual period prevalence). Studies were also stratified by the location of participants (i.e., community-only, community and institution, institution-only) to minimize confounding by disease severity. Studies were included in the meta-analysis if they reported the estimate with 95% confidence intervals (CI95%), the number of AD cases along with overall sample size, or the information with which to calculate an estimate. Additionally, subgroup meta-analysis was only performed if more than one study was available for each subgroup (e.g., a region could have been omitted from this analysis if only one study was available in a region; however, if more than one study was included in the other regions, these data were then analyzed).

To compare study quality characteristics across groups (i.e., continent), ANOVA testing was utilized to determine differences. To assess for significant between-study heterogeneity, the Cochrane Q statistic was calculated and I 2 was employed to quantify the magnitude. All the pooled estimates and 95% confidence intervals were calculated using random-effects models. Publication bias was investigated visually using funnel plots and statistically using Begg’s,Reference Begg and Mazumdar 23 Egger’sReference Egger and Smith 24 and the trim-and-fill tests. The trim-and-fill method identifies funnel plot asymmetry by imputing the effect estimates of potentially missing studies and assessing the influence of these studies on the pooled estimate. For all tests, a value of p less than 0.05 was deemed to be significant. All statistical analyses were carried out in R version 2.14. 25 The meta package was used to produce the pooled estimates, forest plots and publication bias assessments.Reference Schwarzer 26 The metafor package was used to conduct the meta-regression using restricted maximum-likelihood estimation.Reference Viechtbauer 27

Results

Identification and Description of Studies

The search strategy yielded a total of 16,066 citations, including duplicates (8743 from MEDLINE, 7323 from EMBASE) (Figure 1). After screening titles and abstracts, 707 articles were selected for full-text review. Of them, 547 were excluded (230 international studies were published before 2000, 164 did not report incidence or prevalence of dementia, 114 were not population-based, 39 did not report original data). The updating of the search and hand searching the references led to an additional 4 and 12 articles, respectively. Among the 176 eligible papers meeting the inclusion criteria, 57 were excluded, as they did not report on the incidence or prevalence of AD dementia. A total of 119 papers reported on AD dementia.

Figure 1

Study flow diagram.

The characteristics of the 119 included studies are shown in Tables 1-3. Seventy-five reported on prevalence, 43 on incidence and 1 on both. Forty-four studies provided data from Europe, 36 from Asia, 32 from North America, 5 from South America, 2 from Africa and 2 from Australia (2 studies reported data from more than one continent). Nine studies reported on those aged 60+, 68 on those 65+ and 19 on those 70+.

Table 1

Studies Reporting on the Prevalence of Alzheimer’s Disease

Table 2

Studies Reporting on the Incidence Rate of Alzheimer’s Disease

Table 3

Studies Reporting on the Incidence Proportion of Alzheimer’s Disease

Prevalence of AD

Forty-five articles 28 - Reference Li, Yan, Li, Zhang, Liu and Jie 72 reported on the point prevalence of AD dementia, with 20 eligible for inclusion in the meta-analysis of those aged 60+. 28 , Reference Anttila, Helkala, Viitanen, Kareholt, Fratiglioni and Winblad 29 , Reference Bermejo-Pareja, Benito-Leon, Vega, Olazaran, de Toledo and Diaz-Guzman 31 , Reference Bottino, Azevedo, Tatsch, Hototian, Moscoso and Folquitto 33 , Reference Camicioli, Willert, Lear, Grossmann, Kaye and Butterfield 35 , Reference Chen, Chiu, Tang, Chiu, Chang and Su 36 , Reference de Jesus Llibre, Fernandez, Marcheco, Contreras, Lopez and Otero 38 , Reference de Silva, Gunatilake and Smith 39 , Reference Gurvit, Emre, Tinaz, Bilgic, Hanagasi and Sahin 42 , Reference Herrera, Caramelli, Silveira and Nitrini 45 , Reference Ikeda, Hokoishi, Maki, Nebu, Tachibana and Komori 46 , Reference Kivipelto, Helkala, Laakso, Hanninen, Hallikainen and Alhainen 48 , Reference Rovio, Kareholt, Helkala, Viitanen, Winblad and Tuomilehto 57 , Reference Shaji, Bose and Verghese 60 - Reference Suh, Kim and Cho 63 , Reference Wada-Isoe, Uemura, Suto, Doi, Imamura and Hayashi 65 , Reference Yamada, Hattori, Miura, Tanabe and Yamori 67 , Reference Bowirrat, Friedland, Farrer, Baldwin and Korczyn 70 In community-only settings, the point prevalence among those 60+ years of age was 40.19 (CI95%: 29.06-55.59) per 1000 (Figure 2). Point prevalence estimates in the community ranged from a low of 15.51 per 1000 in one study from IndiaReference Shaji, Bose and Verghese 60 to a high of 204.13 per 1000 in a study from Israel.Reference Bowirrat, Friedland, Farrer, Baldwin and Korczyn 70 The pooled point prevalence in those 60+ in combined community and institution studies was 26.57 (CI95%: 11.83-59.69) per 1000. In community and institution studies, point prevalence estimates ranged from a low of 12.34 per 1000 in a study from the United StatesReference Camicioli, Willert, Lear, Grossmann, Kaye and Butterfield 35 to a high of 51.00 per 1000 in a study from Canada. 28 The pooled point prevalence of AD among those 60+ in institution-only settings was 226.97 (CI95%: 88.23-583.87).

Figure 2

Pooled point prevalence of Alzheimer’s Disease.

Thirty studies reported on the period prevalence of AD,Reference Andreasen, Blennow, Sjodin, Winblad and Svardsudd 73 - Reference Zhao, Zhou, Ding, Guo and Hong 103 with 10 eligible for inclusion in the meta-analysis of those 60+.Reference Das, Biswas, Roy, Bose, Roy and Banerjee 77 , Reference Gascon-Bayarri, Rene, Del Barrio, De Pedro-Cuesta, Ramon and Manubens 82 , Reference Gavrila, Antunez, Tormo, Carles, Garcia Santos and Parrilla 83 , Reference Jhoo, Kim, Huh, Lee, Park and Lee 87 , Reference Lee, Lee, Ju, Lee, Kim and Jhoo 89 - Reference Lopez, Kuller, Fitzpatrick, Ives, Becker and Beauchamp 91 , Reference Scazufca, Menezes, Vallada, Crepaldi, Pastor-Valero and Coutinho 99 , Reference Vanhanen, Koivisto, Moilanen, Helkala, Hanninen and Soininen 100 , Reference Xu, Qiu, Gatz, Pedersen, Johansson and Fratiglioni 102 In community settings, the pooled annual period prevalence among those aged 60+ was 30.4 (CI95%: 15.6-59.1) per 1000 (Figure 3). In combined community and institution settings, the pooled annual period prevalence was 44.0 (CI95%: 19.9-97.1) per 1000. A single study from an institution in the United States reported an annual period prevalence of 101.0 (CI95%: 89.4-114.1) per 1000.Reference Magaziner, German, Zimmerman, Hebel, Burton and Gruber-Baldini 93 Annual period prevalence estimates for any setting ranged from 1.1 per 1000 in a community study from IndiaReference Das, Biswas, Roy, Bose, Roy and Banerjee 77 to 123.0 in a community study from the United States.Reference Lopez, Kuller, Fitzpatrick, Ives, Becker and Beauchamp 91

Figure 3

Pooled period prevalence of Alzheimer’s disease.

Incidence of AD

Fourteen studies reported on the incidence proportion of AD,Reference Cornelius, Fastbom, Winblad and Viitanen 104 - Reference Zandi, Carlson, Plassman, Welsh-Bohmer, Mayer and Steffens 117 with six included in the meta-analysis of 60+ studies.Reference Ganguli, Dodge, Chen, Belle and DeKosky 107 , Reference Hendrie, Ogunniyi, Hall, Baiyewu, Unverzagt and Gureje 108 , Reference Kuller, Lopez, Jagust, Becker, DeKosky and Lyketsos 111 , Reference Miech, Breitner, Zandi, Khachaturian, Anthony and Mayer 113 , Reference Morris, Evans, Bienias, Tangney, Bennett and Aggarwal 114 , Reference Seshadri, Beiser, Selhub, Jacques, Rosenberg and D’Agostino 116 In community settings, the pooled annual incidence proportion among those aged 60+ was 34.1 (CI95%: 16.4-70.9) per 1000 (Figure 4). A single U.S. study reported on the annual incidence proportion in combined community and institution settings with an estimate of 27.2 (CI95%: 22.2-33.3) per 1000.Reference Evans, Bennett, Wilson, Bienias, Morris and Scherr 105 There were no studies from an institution-only setting. Annual incidence proportion estimates for any setting ranged from 11.5 per 1000 in a community study from NigeriaReference Hendrie, Ogunniyi, Hall, Baiyewu, Unverzagt and Gureje 108 to 97.8 per 1000 in a community study from the United States.Reference Kuller, Lopez, Jagust, Becker, DeKosky and Lyketsos 111

Figure 4

Pooled incidence proportion of Alzheimer’s disease.

Thirty studies reported on the incidence rate of AD,Reference Li, Yan, Li, Zhang, Liu and Jie 72 , Reference Bermejo-Pareja, Benito-León, Vega, Medrano and Román 118 - Reference Waite, Broe, Grayson and Creasey 146 with 11 eligible for inclusion in the meta-analysis of those 60+.Reference Bermejo-Pareja, Benito-León, Vega, Medrano and Román 118 , Reference Fitzpatrick, Kuller, Ives, Lopez, Jagust and Breitner 122 , Reference Kukull, Higdon, Bowen, McCormick, Teri and Schellenberg 126 - Reference Lee, Chang, Jang, Chang, Suh and Jung 129 , Reference Perez, Helmer, Dartigues, Auriacombe and Tison 136 , Reference Ravaglia, Forti, Maioli, Martelli, Servadei and Brunetti 140 , Reference Tang, Cross, Andrews, Jacobs, Small and Bell 143 - Reference Vermeer, Prins, den Heijer, Hofman, Koudstaal and Breteler 145 In community-only settings, the pooled incidence rate of AD among those 60+ was 15.8 (CI95%: 12.9-19.4) per 1000 person-years (Figure 5). A single Italian study reported on the incidence rate in combined community and institution settings with an estimate of 7.0 (CI95%: 5.5-8.9) per 1000 person-years.Reference Di Carlo, Baldereschi, Amaducci, Lepore, Bracco and Maggi 120 There were no studies from an institution-only setting. The lowest estimate for any setting was 7.0 (CI95%: 4.8-10.3) per 1000 person-years in a community study from the NetherlandsReference Vermeer, Prins, den Heijer, Hofman, Koudstaal and Breteler 145 and the aforementioned study from Italy, and the highest 30.0 (CI95%: 25.4-35.5) per 1000 person-years in a community study from the United States.Reference Tang, Cross, Andrews, Jacobs, Small and Bell 143

Figure 5

Pooled incidence rate of Alzheimer’s disease.

Sources of Heterogeneity

The effect of important potential sources of heterogeneity (i.e., age, sex, diagnostic criteria, location [continent], time [when the study was done]) on incidence and prevalence estimates in those aged 60+ was assessed using univariate meta-regressions.

Age

Increasing age was associated with increasing point prevalence, period prevalence, incidence rate and incidence proportion estimates (p<0.001).

Sex

Though the differences did not reach statistical significance (p values ranged from 0.102 to 0.582), estimates of incidence and prevalence by sex of the subjects were higher in females than in males, in the 22 studies that reported on this.

Diagnostic Criteria for AD

Within community settings, DSM–IV criteria 147 (n=2) produced a statistically significant (p=0.044) higher estimate for AD dementia point prevalence (91.7 [CI95%: 19.0-442.8] per 1000) than those based on NINCDS–ADRDA criteria for probable ADReference McKhann, Drachman, Folstein, Katzman, Price and Stadlan 148 (n=14; 38.2 [CI95%: 31.3-46.6] per 1000). No statistically significant differences between the aforementioned criteria were seen for period prevalence in the community (p = 0.065), though the association was in the same direction as seen in the pooled point prevalence. All incidence studies used NINCDS–ADRDA criteria for probable AD.

Location

Within community settings, the estimated annual period prevalence for North America (n = 2; 103.6 [CI95%: 73.4-146.1] per 1000) was significantly higher than those for Asia (n = 4; 11.7 [CI95%: 2.8-48.5] per 1000; p = 0.017) and Europe (n = 2; 31.3 [CI95%: 14.4-67.7] per 1000; p = 0.006). The estimates for single studies for continents were: South America (16.0 [CI95%: 11.3-22.6] per 1000) and Australia (88.0 [CI95%: 82.7-93.7] per 1000). The incidence proportion estimate in a single-community African study (11.5 [CI95%: 9.70-13.64] per 1000) was lower than the estimated incidence proportion from five North American community studies (42.6 [CI95%: 23.0-78.8] per 1000) but could not be subjected to a meta-analysis as we required at least two estimates from a single region to be included.

Time

There was no effect of the time of study initiation, midpoint or conclusion on point prevalence, period prevalence, incidence rate or incidence proportion estimates.

Publication Bias

For the period prevalence, point prevalence, incidence rate and incidence proportion of AD dementia, significant funnel plot asymmetry was not found using Begg’s or Egger’s test (p > 0.05). Upon visual inspection, the funnel plots appeared symmetrical.

Study Quality

The median study quality score for studies reporting on the incidence or prevalence of AD dementia was 6/8 (range 3-8) (Table 4). Study quality did not vary by continent based on the results of ANOVA analyses.

Table 4

Quality assessment scores of Alzheimer’s Disease incidence and prevalence studies

*Note: NR= Not reported; NC= Not clear

Discussion

A substantial societal burden from AD dementia was demonstrated in our systematic review and meta-analyses. In community settings, the point prevalence of AD dementia among those 60+ was 40.2 per 1000, while its incidence proportion was 34.1 per 1000 and incidence rate was 15.8 per 1000 person-years. Despite the large number of studies included in our meta-analysis, the resulting estimates lacked precision at times due to significant statistical heterogeneity. Our finding that the period prevalence of AD dementia in community settings (30.4 per 1000 persons) was lower than the point prevalence (40.2 per 1000 persons) was unexpected and should be interpreted with caution. You would typically expect the opposite finding (i.e., a higher pooled estimate from the period prevalence studies). This was likely due to the significant heterogeneity (i.e., >99% for period prevalence studies) that existed between these two pools of studies, leading to wide confidence intervals. In addition, there were several outliers, particularly in the period prevalence estimates, which ranged from a low of 1.1 in IndiaReference Das, Biswas, Roy, Bose, Roy and Banerjee 77 to a high of 123.0 per 1000 persons in a U.S. study.Reference Lopez, Kuller, Fitzpatrick, Ives, Becker and Beauchamp 91

Our exploration of the sources of this heterogeneity led to several interesting findings. There was an insufficient number of population-based institution studies to do meta-analyses for this setting, but our descriptive analysis indicated that incidence rate for AD dementia is higher in the community while prevalence is greater in institutions. This is not surprising. There are few at-risk individuals within institutions, and the high mortality rate from other causes in the small at-risk institutional group likely means that they will likely die from another cause before they have time to develop AD. The inclusion of an institutionalized sample as well as region-specific variation in the availability of facility-based care and/or likelihood for institutionalization can have a substantial impact on the estimated prevalence of AD dementia in a community.Reference Hendrie, Osuntokun, Hall, Ogunniyi, Hui and Unverzagt 149 Institutionalization typically occurs as a result of the functional impairments, behavioural challenges and associated burden on family caregivers that arise as the disease progresses and largely explain the high prevalence in this setting. Information on the incidence and prevalence of AD stratified by setting is particularly relevant for planning resource allocation. We identified a significant gap when it comes to the population-based epidemiology of AD dementia in institutional and residential settings. Future studies are required to understand the true burden of AD dementia in long-term and supportive care facilities. The use of standardized assessments based on data abstracted from interRAI instruments to provide estimates for the prevalence of dementia in these settings holds promise, but it is unclear whether they could be utilized for estimates of dementia arising specifically from AD.Reference Danila, Hirdes, Maxwell, Marrie, Patten, Pringsheim and Jetté 150

All estimates of incidence and prevalence were higher for females compared to males, though the differences were not statistically different. In economically developed nations, about two-thirds of individuals diagnosed with AD dementia are women.Reference Hebert, Weuve, Scherr and Evans 151 This is primarily due to the fact that women on average live longer than men, and increasing age is the most important non-genetic risk factor for AD dementia. Incidence studies suggest an age-dependent relationship between sex and likelihood of developing AD dementia. One of the studies we included noted differences in incidence rates by sex after 90 years of age.Reference Ruitenberg, Ott, van Swieten, Hofman and Breteler 142 Other reports indicate that the incidence of AD dementia increases with age in both sexes until 85-90 years of age, after which it plateaus for men but continues to increase among women.Reference Andersen, Launer, Dewey, Letenneur, Ott and Copeland 152 , Reference Fratiglioni, Launer, Andersen, Breteler, Copeland and Dartiques 153 A prior meta-analysis reported slightly longer doubling times with increasing age for AD dementia in men compared to women,Reference Ziegler-Graham, Brookmeyer, Johnson and Arrighi 10 while another study reported that women tend to have a higher incidence at very advanced ages.Reference Jorm and Jolley 12 These noted differences between the sexes could be due to methodological issues, the differential impact of historical environmental risk factors, or true biological differences in disease susceptibility between the sexes.Reference Mielke, Vemuri and Rocca 154 Interestingly, recent data suggest that, relative to women, men who survive to older ages may exhibit a lower risk for developing AD because of a healthier cardiovascular risk profile.Reference Chene, Beiser, Au, Preis, Wolf and Dufouil 155

Difficulties examining the effect of the diagnostic criteria utilized to diagnose AD cases were encountered due to the ubiquitous use of NINCDS–ADRDA criteria. However, for point prevalence in community-only settings, DSM–IV criteria were found to produce significantly higher estimates than studies utilizing NINCDS–ADRDA criteria for probable AD (and possibly ICD–10 criteria 156 ); a trend in the same direction was also shown in community period prevalence estimates. The choice and operationalization of diagnostic criteria can have a large effect on estimated incidence and/or prevalence.Reference Erkinjuntti, Ostbye, Steenhuis and Hachinski 157 , Reference Wilson, Weir, Leurgans, Evans, Hebert and Langa 158 In one study, the use of DSM–III criteria led to 29.1% of subjects receiving a dementia diagnosis compared to 13.7% when DSM–IV criteria were employed.Reference Erkinjuntti, Ostbye, Steenhuis and Hachinski 157 Newer diagnostic criteria for AD decouple AD from the presence of a dementia and no longer require the presence of a memory impairment, the impact of which on epidemiological estimates of the incidence and prevalence of AD is yet unknown.Reference McKhann, Knopman, Chertkow, Hyman, Jack and Kawas 159 In the future, a diagnosis of preclinical AD may be made on the basis of biomarkers, though clinical criteria will be required to diagnose symptomatic (i.e., mild cognitive impairment or dementia) AD.Reference Dubois, Feldman, Jacova, Hampel, Molinuevo and Blennow 160 We suspect that the National Institute on Aging–Alzheimer’s Association clinical diagnostic criteria for dementia due to ADReference Lopez, McDade, Riverol and Becker 161 will be used in future incidence and prevalence studies of AD. Studies are needed to assess the potential impact of using these newer diagnostic approaches compared to the criteria that have been used to date on the estimated incidence and prevalence of AD and trends over time.

Estimates of AD dementia incidence and prevalence tended to be higher in North America as compared to Asia, but these differences were not statistically different except for estimates of period prevalence in community settings. Geographical differences in epidemiological estimates of AD could be due to a variety of factors other than true differences in age-specific disease risk, such as differing screening methods and thresholds for diagnosis, age distribution of the assessed population, duration of survival after the onset of AD dementia, overall life expectancy and competing risks.Reference Suh and Shah 17 Nonetheless, the possibility of true regional differences in AD incidence and prevalence has important implications. It is unlikely that the observed findings can be fully explained by differences in life expectancy. While North America has a relatively high life expectancy, estimates of life expectancy are similar or even higher in several Asian countries (e.g., Japan). 162 Similar findings (i.e., lower estimates in Asia) have been reported for Huntington’s disease and Parkinson’s disease, where it is felt that differences in the distribution, life expectancy and degree of stigmatization associated with a diagnosis of the condition may contribute to variations in disease reporting.Reference Pringsheim, Jetté, Frolkis and Steeves 163 , Reference Pringsheim, Wiltshire, Day, Dykeman, Steeves and Jetté 164

The methodology utilized for this systematic review and meta-analysis closely followed established guidelines. We feel we were able to identify most eligible studies as multiple sources of study ascertainment were employed. We found no evidence for publication bias. We did, however, find a good deal of statistical heterogeneity.

In order to accurately plan for future needs, there remains an ongoing requirement to provide accurate estimates of the incidence and prevalence of AD. Relying on older data may lead to either over- or underestimating the resources required if incidence and prevalence rates are changing over time. Though, using meta-regression analysis, we did not find that time had an effect on the incidence or prevalence of AD, this does not preclude the possibility of true changes in age-standardized incidence and/or prevalence rates for dementia from AD occurring either now or in the near future due to changes in the presence of risk factors at a population level.Reference Norton, Matthews, Barnes, Yaffe and Brayne 165 There could well be rising and/or falling rates of AD within specific nations or regions that could be obscured by looking at international changes. For dementia overall, as an example, there is a suggestion that rates are falling in high-rate areas (often high-income countries) and might be rising in low- and middle-income countries, where premature mortality is decreasing.Reference Schrijvers, Verhaaren, Koudstaal, Hofman, Ikram and Breteler 166 , Reference Matthews, Arthur, Barnes, Bond, Jagger and Robinson 167 This underscores the need for future studies on the epidemiology of this important condition.

Disclosures

Kirsten Fiest, Jodie Roberts, Colleen Maxwell, Eric Smith, Alexandra Frolkis, Adrienne Cohen, Andrew Kirk, Dawn Pearson, Tamara Pringsheim, and Andres Venegas-Torres have nothing to disclose.

David Hogan holds the Brenda Strafford Foundation Chair in Geriatric Medicine, though receives no salary support from this.

Nathalie Jetté has the following disclosures: Public Health Agency of Canada, Principal Investigator, research support; Canada Research Chair in Neurological Health Services Research, Researcher, research support; Alberta Innovates Health Solutions Population Health Investigator, Researcher, research support.

Acknowledgments

We thank Ms. Diane Lorenzetti, librarian at the University of Calgary, who guided the development of the search strategy for this systematic review. Our study is part of the National Population Health Study of Neurological Conditions. We acknowledge the membership of the Neurological Health Charities Canada and the Public Health Agency of Canada for their contribution to the success of this initiative. Funding for the study was provided by the Public Health Agency of Canada. The opinions expressed in this publication are those of the authors/researchers and do not necessarily reflect the official views of the Public Health Agency of Canada.

Statement of Authorship

KMF, JIR, CJM, DBH, TP and NJ contributed to study conception and design. KMF, JIR, CJM, DBH, EES, AC, AK, DP, AV-T and NJ contributed to the acquisition of data. KMF and AF conducted the data analysis. KMF, JIR, CJM, DBH, EES and NJ participated in the interpretation of study data. All authors participated in critically revising the manuscript for important intellectual content and gave final approval for the submission of this manuscript and any further submissions of this work.

Supplementary Material

To view supplementary material for this article, please visit http://dx.doi.org/10.1017/cjn.2016.36

References

1. Demakis, GJ. Disability in Alzheimer’s disease: causes, consequences, and economic considerations. J Health Hum Serv Adm. 2007;30:292-305.Google ScholarPubMed
2. Gillespie, P, O'Shea, E, Cullinan, J, Lacey, L, Gallagher, D, Ni Mhaolain, A, et al. The effects of dependence and function on costs of care for Alzheimer’s disease and mild cognitive impairment in Ireland. Int J Geriatr Psychiatry. 2013;28:256-264.CrossRefGoogle ScholarPubMed
3. World Health Organization. The 10 Leading Causes of Death by Broad Income Group. Geneva: World Health Organization; 2008.Google Scholar
4. Brookmeyer, R, Evans, DA, Hebert, L, Langa, KM, Heeringa, SG, Plassman, BL, et al. National estimates of the prevalence of Alzheimer’s disease in the United States. Alzheimers Dement. 2011;7:61-73.CrossRefGoogle ScholarPubMed
5. Alzheimer, A. Über einen eigenartigen schweren Erkrankungsprozeβ der Hirnrincle. Neurol Zentral. 1906;25:1134.Google Scholar
6. Doody, RS, Stevens, JC, Beck, C, Dubinsky, RM, Kaye, JA, Gwyther, L, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154-1166.CrossRefGoogle Scholar
7. Morris, JC. Dementia update 2005. Alzheimer Dis Assoc Disord. 2005;19:100-117.Google Scholar
8. World Health Organization. Dementia: A Public Health Priority. Geneva: World Health Organization; 2012.Google Scholar
9. Alzheimer’s Disease International. World Alzheimer Report 2015: The Global Impact of Dementia. An Analysis of Prevalence, Incidence, Cost and Trends. London: Alzheimer’s Disease International; 2015.Google Scholar
10. Ziegler-Graham, K, Brookmeyer, R, Johnson, E, Arrighi, HM. Worldwide variation in the doubling time of Alzheimer’s disease incidence rates. Alzheimers Dement. 2008;4:316-323.CrossRefGoogle ScholarPubMed
11. Kukull, WA, Higdon, R, Bowen, JD, McCormick, WC, Teri, L, Schellenberg, GD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol. 2002;59:1737-1746.CrossRefGoogle ScholarPubMed
12. Jorm, AF, Jolley, D. The incidence of dementia: a meta-analysis. Neurology. 1998;51:728-733.CrossRefGoogle ScholarPubMed
13. Jorm, AF, Korten, AE, Henderson, AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand. 1987;76:465-479.CrossRefGoogle ScholarPubMed
14. Rockwood, K, Stadnyk, K. The prevalence of dementia in the elderly: a review. Can J Psychiatry. 1994;39:253-257.CrossRefGoogle ScholarPubMed
15. Fratiglioni, L, De Ronchi, D, Aguero-Torres, H. Worldwide prevalence and incidence of dementia. Drugs Aging. 1999;15:365-375.Google Scholar
16. Clarfield, AM. The decreasing prevalence of reversible dementias: an updated meta-analysis. Arch Intern Med. 2003;163:2219-2229.Google Scholar
17. Suh, GH, Shah, A. A review of the epidemiological transition in dementia: cross-national comparisons of the indices related to Alzheimer’s disease and vascular dementia. Acta Psychiatr Scand. 2001;104:4-11.Google Scholar
18. Caesar-Chavannes, C, MacDonald, S. Cross-Canada Forum: National Population Health Study of Neurological Conditions in Canada. Chronic Dis Inj Can. 2013;33:188-191.CrossRefGoogle ScholarPubMed
19. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.Google Scholar
20. EndNote X5. . New York: Thompson Reuters, 2011. Available from http://endnote.com/downloads/available-updates.Google Scholar
21. Loney, PL, Chambers, LW, Bennett, KJ, Roberts, JG, Stratford, PW. Critical appraisal of the health research literature: prevalence or incidence of a health problem. Chronic Dis Inj Can. 1998;19:170-176.Google ScholarPubMed
22. Boyle, MH.. Guidelines for evaluating prevalence studies. Evid Based Ment Health. 1998;1:37-39.CrossRefGoogle Scholar
23. Begg, C, Mazumdar, M.. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.CrossRefGoogle Scholar
24. Egger, M, Smith, G. Bias in meta-analysis detected by simple, graphical test. Br Med J. 1997;315:629-634.CrossRefGoogle ScholarPubMed
25. R: A Language and Environment for Statistical Computing [computer program]. Vienna, Austria: R Foundation for Statistical Computing; 2011.Google Scholar
26. Schwarzer, G. meta: Meta-Analysis with R. R package version 16-1; 2010.Google Scholar
27. Viechtbauer, W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1-48.CrossRefGoogle Scholar
28. Canadian study of health and aging: study methods and prevalence of dementia. CMAJ. 1994;150:899-913.Google Scholar
29. Anttila, T, Helkala, EL, Viitanen, M, Kareholt, I, Fratiglioni, L, Winblad, B, et al. Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: a prospective population based study. BMJ. 2004;329:539.Google Scholar
30. Benedetti, MD, Salviati, A, Filipponi, S, Manfredi, M, De Togni, L, Gomez Lira, M, et al. Prevalence of dementia and apolipoprotein E genotype distribution in the elderly of Buttapietra, Verona Province, Italy. Neuroepidemiology. 2002;21:74-80.Google Scholar
31. Bermejo-Pareja, F, Benito-Leon, J, Vega, S, Olazaran, J, de Toledo, M, Diaz-Guzman, J, et al. Consistency of clinical diagnosis of dementia in NEDICES: A population-based longitudinal study in Spain. J Geriatr Psychiatry Neurol. 2009;22:246-255.Google Scholar
32. Borroni, B, Alberici, A, Grassi, M, Rozzini, L, Turla, M, Zanetti, O, et al. Prevalence and demographic features of early-onset neurodegenerative dementia in Brescia County, Italy. Alzheimer Dis Assoc Disord. 2011;25:341-344.Google Scholar
33. Bottino, CMC, Azevedo, D Jr, Tatsch, M, Hototian, SR, Moscoso, MA, Folquitto, J, et al. Estimate of dementia prevalence in a community sample from São Paulo, Brazil. Dement Geriatr Cogn Disord. 2008;26:291-299.Google Scholar
34. Bowirrat, A, Treves, TA, Friedland, RP, Korczyn, AD. Prevalence of Alzheimer’s type dementia in an elderly Arab population. Eur J Neurol. 2001;8:119-123.Google Scholar
35. Camicioli, R, Willert, P, Lear, J, Grossmann, S, Kaye, J, Butterfield, P. Dementia in rural primary care practices in Lake County, Oregon. J Geriatr Psychiatry Neurol. 2000;13:87-92.Google Scholar
36. Chen, TF, Chiu, MJ, Tang, LY, Chiu, YH, Chang, SF, Su, CL, et al. Institution type-dependent high prevalence of dementia in long-term care units. Neuroepidemiology. 2007;28:142-149.Google Scholar
37. Dahl, A, Berg, S, Nilsson, SE. Identification of dementia in epidemiological research: a study on the usefulness of various data sources. Aging Clin Exp Res. 2007;19:381-389.CrossRefGoogle Scholar
38. de Jesus Llibre, J, Fernandez, Y, Marcheco, B, Contreras, N, Lopez, AM, Otero, M, et al. Prevalence of dementia and Alzheimer’s disease in a Havana municipality: a community-based study among elderly residents. MEDICC Rev. 2009;11:29-35.Google Scholar
39. de Silva, HA, Gunatilake, SB, Smith, AD. Prevalence of dementia in a semi-urban population in Sri Lanka: report from a regional survey. Int J Geriatr Psychiatry. 2003;18:711-715.CrossRefGoogle Scholar
40. Fish, M, Bayer, AJ, Gallacher, JEJ, Bell, T, Pickering, J, Pedro, S, et al. Prevalence and pattern of cognitive impairment in a community cohort of men in South Wales: methodology and findings from the Caerphilly Prospective Study. Neuroepidemiology. 2008;30:25-33.CrossRefGoogle Scholar
41. Fujishima, M, Kiyohara, Y.. Incidence and risk factors of dementia in a defined elderly Japanese population: the Hisayama study. Ann N Y Acad Sci. 2002;977:1-8.CrossRefGoogle Scholar
42. Gurvit, H, Emre, M, Tinaz, S, Bilgic, B, Hanagasi, H, Sahin, H, et al. The prevalence of dementia in an urban Turkish population. Am J Alzheimers Dis Other Demen. 2008;23:67-76.CrossRefGoogle Scholar
43. Hall, KS, Gao, S, Baiyewu, O, Lane, KA, Gureke, O, Shen, J, et al. Prevalence rates for dementia and Alzheimer’s disease in African Americans: 1992 versus 2001. Alzheimer’s Dement. 2009;5:227-233.Google Scholar
44. Harvey, RJ, Skelton-Robinson, M, Rossor, MN. The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry. 2003;74:1206-1209.CrossRefGoogle ScholarPubMed
45. Herrera, E Jr, Caramelli, P, Silveira, ASB, Nitrini, R. Epidemiologic survey of dementia in a community-dwelling Brazilian population. Alzheimer Dis Assoc Disord. 2002;16:103-108.Google Scholar
46. Ikeda, M, Hokoishi, K, Maki, N, Nebu, A, Tachibana, N, Komori, K, et al. Increased prevalence of vascular dementia in Japan: a community-based epidemiological study. Neurology. 2001;57:839-844.Google Scholar
47. Ikejima, C, Yasuno, F, Mizukami, K, Sasaki, M, Tanimukai, S, Asada, T. Prevalence and causes of early-onset dementia in Japan: a population-based study. Stroke. 2009;40:2709-2714.Google Scholar
48. Kivipelto, M, Helkala, EL, Laakso, M, Hanninen, T, Hallikainen, M, Alhainen, K, et al. Apolipoprotein E e4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137:149-155.CrossRefGoogle Scholar
49. Kivipelto, M, Helkala, EL, Laakso, M, Hanninen, T, Hallikainen, M, Alhainen, K, et al.. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ. 2001;322:1447-1451.Google Scholar
50. Mathuranath, PS, Cherian, PJ, Mathew, R, Kumar, S, George, A, Alexander, A, et al. Dementia in Kerala, South India: prevalence and influence of age, education and gender. Int J Geriatr Psychiatry. 2010;25:290-297.Google Scholar
51. Meguro, K, Ishii, H, Yamaguchi, S, Ishizaki, J, Shimada, M, Sato, M, et al. Prevalence of dementia and dementing diseases in Japan: the Tajiri Project. Arch Neurol. 2002;59:1109-1114.CrossRefGoogle ScholarPubMed
52. Nunes, B, Silva, RD, Cruz, VT, Roriz, JM, Pais, J, Silva, MC. Prevalence and pattern of cognitive impairment in rural and urban populations from Northern Portugal. BMC Neurol. 2010;10:42.CrossRefGoogle Scholar
53. Plassman, BL, Langa, KM, Fisher, GG, Fisher, GG, Heeringa, SG, Weir, DR, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29:125-132.CrossRefGoogle ScholarPubMed
54. Polvikoski, T, Sulkava, R, Myllykangas, L, Notkola, IL, Niinisto, L, Verkkoniemi, A, et al. Prevalence of Alzheimer’s disease in very elderly people: a prospective neuropathological study. Neurology. 2001;56:1690-1696.Google Scholar
55. Rahkonen, T, Eloniemi-Sulkava, U, Rissanen, S, Vatanen, A, Viramo, P, Sulkava, R. Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J Neurol Neurosurg Psychiatry. 2003;74:720-724.CrossRefGoogle ScholarPubMed
56. Rosenblatt, A, Samus, QM, Steele, CD, Baker, AS, Harper, MG, Brandt, J, et al. The Maryland Assisted Living Study: prevalence, recognition, and treatment of dementia and other psychiatric disorders in the assisted-living population of central Maryland. J Am Geriatr Soc. 2004;52:1618-1625.Google Scholar
57. Rovio, S, Kareholt, I, Helkala, EL, Viitanen, M, Winblad, B, Tuomilehto, J, et al. Leisure-time physical activity and the risk of dementia and Alzheimer’s disease. Lancet Neurol. 2005;4:705-711.Google Scholar
58. Sahadevan, S, Saw, SM, Gao, W, Tan, LC, Chin, JJ, Hong, CY, et al. Ethnic differences in Singapore’s dementia prevalence: the stroke, Parkinson’s disease, epilepsy, and dementia in Singapore study. J Am Geriatr Soc. 2008;56:2061-2068.Google Scholar
59. Sekita, A, Ninomiya, T, Tanizaki, Y, Doi, Y, Hata, J, Yonemoto, K, et al. Trends in prevalence of Alzheimer’s disease and vascular dementia in a Japanese community: the Hisayama Study. Acta Psychiatr Scand. 2010;122:319-325.CrossRefGoogle Scholar
60. Shaji, S, Bose, S, Verghese, A. Prevalence of dementia in an urban population in Kerala, India. Br J Psychiatry. 2005;187:90.Google Scholar
61. Spada, RS, Stella, G, Calabrese, S, Bosco, P, Anello, G, Gueant-Rodriguez, RM, et al. Prevalence of dementia in mountainous village of Sicily. J Neurol Sci. 2009;283:62-65.CrossRefGoogle ScholarPubMed
62. Stevens, T, Livingston, G, Kitchen, G, Manela, M, Walker, Z, Katona, C. Islington study of dementia subtypes in the community. Br J Psychiatry. 2002;180:270-276.CrossRefGoogle ScholarPubMed
63. Suh, GH, Kim, JK, Cho, MJ. Community study of dementia in the older Korean rural population. Aust N Z J Psychiatry. 2003;37:606-612.Google Scholar
64. Vas, CJ, Pinto, C, Panikker, D, Noronha, S, Deshpande, N, Kulkarni, L, et al. Prevalence of dementia in an urban Indian population. Int Psychogeriatr. 2001;13:439-450.CrossRefGoogle Scholar
65. Wada-Isoe, K, Uemura, Y, Suto, Y, Doi, K, Imamura, K, Hayashi, A, et al. Prevalence of dementia in the rural island town of Ama-cho, Japan. Neuroepidemiology. 2009;32:101-106.Google Scholar
66. Wakutani, Y, Kusumi, M, Wada, K, Kawashima, M, Ishizaki, K, Mori, M, et al. Longitudinal changes in the prevalence of dementia in a Japanese rural area. Psychogeriatrics. 2007;7:150-154.Google Scholar
67. Yamada, T, Hattori, H, Miura, A, Tanabe, M, Yamori, Y. Prevalence of Alzheimer’s disease, vascular dementia and dementia with Lewy bodies in a Japanese population. Psychiatry Clin Neurosci. 2001;55:21-25.Google Scholar
68. Zhang, ZX, Zahner, GEP, Román, GC, Liu, J, Hong, Z, Qu, QM, et al. Dementia subtypes in China: prevalence in Beijing, Xian, Shanghai, and Chengdu. Arch Neurol. 2005;62:447-453.Google Scholar
69. Zhou, DF, Wu, CS, Qi, H, Fan, JH, Sun, XD, Como, P, et al. Prevalence of dementia in rural China: impact of age, gender and education. Acta Neurol Scand. 2006;114:273-280.Google Scholar
70. Bowirrat, A, Friedland, RP, Farrer, L, Baldwin, C, Korczyn, A. Genetic and environmental risk factors for Alzheimer’s disease in Israeli Arabs. J Mol Neurosci. 2002;19:239-245.Google Scholar
71. Bowirrat, A, Friedland, RP, Korczyn, AD. Vascular dementia among elderly Arabs in Wadi Ara. J Neurol Sci. 2002;203–4:73-76.CrossRefGoogle Scholar
72. Li, S, Yan, F, Li, G, Zhang, W, Liu, J, Jie, X, et al. Is the dementia rate increasing in Beijing? Prevalence and incidence of dementia 10 years later in an urban elderly population. Acta Psychiatr Scand. 2007;115:73-79.Google Scholar
73. Andreasen, N, Blennow, K, Sjodin, C, Winblad, B, Svardsudd, K. Prevalence and incidence of clinically diagnosed memory impairments in a geographically defined general population in Sweden: The Piteå Dementia Project. Neuroepidemiology. 1999;18:144-155.CrossRefGoogle Scholar
74. Arslantas, D, Ozbabalik, D, Metintas, S, Ozkan, S, Kalyoncu, C, Ozdemir, G, et al. Prevalence of dementia and associated risk factors in Middle Anatolia, Turkey. J Clin Neurosci. 2009;16:1455-1459.Google Scholar
75. Banerjee, TK, Mukherjee, CS, Dutt, A, Shekhar, A, Hazra, A. Cognitive dysfunction in an urban Indian population: some observations. Neuroepidemiology. 2008;31:109-114.CrossRefGoogle Scholar
76. Borjesson-Hanson, A, Edin, E, Gislason, T, Skoog, I.. The prevalence of dementia in 95 year olds. Neurology. 2004;63:2436-2438.Google Scholar
77. Das, SK, Biswas, A, Roy, J, Bose, P, Roy, T, Banerjee, TK, et al. Prevalence of major neurological disorders among geriatric population in the metropolitan city of Kolkata. J Assoc Physicians India. 2008;56:175-181.Google Scholar
78. Das, SK, Biswas, A, Roy, T, Banerjee, TK, Mukherjee, CS, Raut, DK, et al. A random sample survey for prevalence of major neurological disorders in Kolkata. Indian J Med Res. 2006;124:163-172.Google Scholar
79. Demirovic, J, Prineas, R, Loewenstein, D, Bean, J, Duara, R, Sevush, S, et al. Prevalence of dementia in three ethnic groups: the South Florida program on aging and health. Ann Epidemiol. 2003;13:472-478.Google Scholar
80. Ebly, EM, Parhad, IM, Hogan, DB, Fung, TS. Prevalence and types of dementia in the very old: results from the Canadian Study of Health and Aging. Neurology. 1994;44:1593-1600.Google Scholar
81. Ganguli, M, Chandra, V, Kamboh, MI, Johnston, JM, Dodge, HH, Thelma, BK, et al. Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US Cross-National Dementia Study. Arch Neurol. 2000;57:824-830.Google Scholar
82. Gascon-Bayarri, J, Rene, R, Del Barrio, JL, De Pedro-Cuesta, J, Ramon, JM, Manubens, JM, et al. Prevalence of dementia subtypes in El Prat de Llobregat, Catalonia, Spain: the PRATICON study. Neuroepidemiology. 2007;28:224-234.Google Scholar
83. Gavrila, D, Antunez, C, Tormo, MJ, Carles, R, Garcia Santos, JM, Parrilla, G, et al. Prevalence of dementia and cognitive impairment in Southeastern Spain: the Ariadna study. Acta Neurol Scand. 2009;120:300-307.CrossRefGoogle ScholarPubMed
84. Gislason, TB, Sjogren, M, Larsson, L, Skoog, I. The prevalence of frontal variant frontotemporal dementia and the frontal lobe syndrome in a population-based sample of 85 year olds. J Neurol Neurosurg Psychiatry. 2003;74:867-871.Google Scholar
85. Guerchet, M, M'Belesso, P, Mouanga, AM, Bandzouzi, B, Tabo, A, Houinato, DS, et al. Prevalence of dementia in elderly living in two cities of Central Africa: the EDAC survey. Dement Geriatr Cogn Disord. 2010;30:261-268.Google Scholar
86. Ikeda, M, Fukuhara, R, Shigenobu, K, Hokoishi, K, Maki, N, Nebu, A, et al. Dementia-associated mental and behavioural disturbances in elderly people in the community: findings from the first Nakayama study. J Neurol Neurosurg Psychiatry. 2004;75:146-148.Google Scholar
87. Jhoo, JH, Kim, KW, Huh, Y, Lee, SB, Park, JH, Lee, JJ, et al. Prevalence of dementia and its subtypes in an elderly urban Korean population: results from the Korean Longitudinal Study on Health and Aging (KLoSHA). Dement Geriatr Cogn Disord. 2008;26:270-276.Google Scholar
88. Landi, F, Russo, A, Cesari, M, Barillaro, C, Onder, G, Zamboni, V, et al. The ilSIRENTE study: a prospective cohort study on persons aged 80 years and older living in a mountain community of Central Italy. Aging Clin Exp Res. 2005;17:486-493.Google Scholar
89. Lee, DY, Lee, JH, Ju, YS, Lee, KU, Kim, KW, Jhoo, JH, et al. The prevalence of dementia in older people in an urban population of Korea: the Seoul study. J Am Geriatr Soc. 2002;50:1233-1239.Google Scholar
90. Li, G, Rhew, IC, Shofer, JB, Rhew, IC, Kukull, WA, Peskind, ER, et al. Age-varying association between blood pressure and risk of dementia in those aged 65 and older: a community-based prospective cohort study. J Am Geriatr Soc. 2007;55:1161-1167.Google Scholar
91. Lopez, OL, Kuller, LH, Fitzpatrick, A, Ives, D, Becker, JT, Beauchamp, N. Evaluation of dementia in the cardiovascular health cognition study. Neuroepidemiology. 2003;22:1-12.Google Scholar
92. Lovheim, H, Karlsson, S, Gustafson, Y. The use of central nervous system drugs and analgesics among very old people with and without dementia. Pharmacoepidemiol Drug Saf. 2008;17:912-918.Google Scholar
93. Magaziner, J, German, P, Zimmerman, SI, Hebel, JR, Burton, L, Gruber-Baldini, AL, et al. The prevalence of dementia in a statewide sample of new nursing home admissions aged 65 and older: diagnosis by expert panel. Epidemiology of Dementia in Nursing Homes Research Group. Gerontologist. 2000;40:663-672.Google Scholar
94. Maneno, MK, Lee, E, Wutoh, AK, Zuckerman, IH, Jackson, P, Lombardo, FA, et al. National patterns of dementia treatment among elderly ambulatory patients. J Natl Med Assoc. 2006;98:430-435.Google Scholar
95. Manton, KC, Gu, XL, Ukraintseva, SV. Declining prevalence of dementia in the U.S. elderly population. Adv Gerontol. 2005;16:30-37.Google Scholar
96. Molero, AE, Pino-Ramirez, G, Maestre, GE. High prevalence of dementia in a Caribbean population. Neuroepidemiology. 2007;29:107-112.Google Scholar
97. Perkins, AJ, Hui, SL, Ogunniyi, A, Gureje, O, Baiyewu, O, Unverzaqt, FW, et al. Risk of mortality for dementia in a developing country: the Yoruba in Nigeria. Int J Geriatr Psychiatry. 2002;17:566-573.Google Scholar
98. Rockwood, K, Wentzel, C, Hachinski, V, Hogan, DB, MacKnight, C, McDowell, I. Prevalence and outcomes of vascular cognitive impairment: Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology. 2000;54:447-451.Google Scholar
99. Scazufca, M, Menezes, PR, Vallada, HP, Crepaldi, AL, Pastor-Valero, M, Coutinho, LM, et al. High prevalence of dementia among older adults from poor socioeconomic backgrounds in São Paulo, Brazil. Int Psychogeriatr. 2008;20:394-405.Google Scholar
100. Vanhanen, M, Koivisto, K, Moilanen, L, Helkala, EL, Hanninen, T, Soininen, H, et al. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology. 2006;67:843-847.Google Scholar
101. Wangtongkum, S, Sucharitkul, P, Silprasert, N, Inthrachak, R. Prevalence of dementia among population age over 45 years in Chiang Mai, Thailand. J Med Assoc Thai. 2008;91:1685-1690.Google Scholar
102. Xu, W, Qiu, C, Gatz, M, Pedersen, NL, Johansson, B, Fratiglioni, L. Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes. 2009;58:71-77.Google Scholar
103. Zhao, Q, Zhou, B, Ding, D, Guo, Q, Hong, Z. Prevalence, mortality, and predictive factors on survival of dementia in Shanghai, China. Alzheimer Dis Assoc Disord. 2010;24:151-158.CrossRefGoogle ScholarPubMed
104. Cornelius, C, Fastbom, J, Winblad, B, Viitanen, M. Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population. Neuroepidemiology. 2004;23:135-143.Google Scholar
105. Evans, DA, Bennett, DA, Wilson, RS, Bienias, JL, Morris, MC, Scherr, PA, et al. Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol. 2003;60:185-189.Google Scholar
106. Forti, P, Pisacane, N, Rietti, E, Lucicesare, A, Olivelli, V, Mariani, E, et al. Metabolic syndrome and risk of dementia in older adults. J Am Geriatr Soc. 2010;58:487-492.CrossRefGoogle ScholarPubMed
107. Ganguli, M, Dodge, HH, Chen, P, Belle, S, DeKosky, ST. Ten-year incidence of dementia in a rural elderly US community population: the MoVIES Project. Neurology. 2000;54:1109-1116.Google Scholar
108. Hendrie, HC, Ogunniyi, A, Hall, KS, Baiyewu, O, Unverzagt, FW, Gureje, O, et al. Incidence of dementia and Alzheimer disease in two communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA. 2001;285:739-747.Google Scholar
109. Kawas, C, Gray, S, Brookmeyer, R, Fozard, J, Zonderman, A. Age-specific incidence rates of Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology. 2000;54:2072-2077.Google Scholar
110. Knopman, DS, Rocca, WA, Cha, RH, Edland, SD, Kokmen, E. Survival study of vascular dementia in Rochester, Minnesota. Arch Neurol. 2003;60:85-90.Google Scholar
111. Kuller, LH, Lopez, OL, Jagust, WJ, Becker, JT, DeKosky, ST, Lyketsos, C, et al. Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Neurology. 2005;64:1548-1552.Google Scholar
112. Lopez, OL, Kuller, LH, Becker, JT, Jaqust, WJ, DeKosky, ST, Fitzpatrick, A, et al. Classification of vascular dementia in the Cardiovascular Health Study Cognition Study. Neurology. 2005;64:1539-1547.CrossRefGoogle ScholarPubMed
113. Miech, RA, Breitner, JCS, Zandi, PP, Khachaturian, AS, Anthony, JC, Mayer, L. Incidence of AD may decline in the early 90s for men, later for women: The Cache County Study. Neurology. 2002;58:209-218.Google Scholar
114. Morris, MC, Evans, DA, Bienias, JL, Tangney, CC, Bennett, DA, Aggarwal, N, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA. 2002;287:3230-3237.Google Scholar
115. Piguet, O, Grayson, DA, Creasey, H, Bennett, HP, Brooks, WS, Waite, LM, et al. Vascular risk factors, cognition and dementia incidence over 6 years in the Sydney Older Persons Study. Neuroepidemiology. 2003;22:165-171.Google Scholar
116. Seshadri, S, Beiser, A, Selhub, J, Jacques, PF, Rosenberg, IH, D’Agostino, RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s Disease. N Engl J Med. 2002;346:476-483.Google Scholar
117. Zandi, PP, Carlson, MC, Plassman, BL, Welsh-Bohmer, KA, Mayer, LS, Steffens, DC, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: The Cache County Study. JAMA. 2002;288:2123-2129.Google Scholar
118. Bermejo-Pareja, F, Benito-León, J, Vega, S, Medrano, MJ, Román, GC, Neurological Disorders in Central Spain (NEDICES) Study Group. Incidence and subtypes of dementia in three elderly populations of central Spain. J Neurol Sci. 2008;264:63-72.Google Scholar
119. Chandra, V, Pandav, R, Dodge, HH, Johnston, JM, Belle, SH, DeKosky, ST, et al. Incidence of Alzheimer’s disease in a rural community in India: the Indo-US study. Neurology. 2001;57:985-989.Google Scholar
120. Di Carlo, A, Baldereschi, M, Amaducci, L, Lepore, V, Bracco, L, Maggi, S, et al. Incidence of dementia, Alzheimer’s disease, and vascular dementia in Italy: The ILSA Study. J Am Geriatr Soc. 2002;50:41-48.Google Scholar
121. Edland, SD, Rocca, WA, Petersen, RC, Cha, RH, Kokmen, E. Dementia and Alzheimer disease incidence rates do not vary by sex in Rochester, Minnesota. Arch Neurol. 2002;59:1589-1593.Google Scholar
122. Fitzpatrick, AL, Kuller, LH, Ives, DG, Lopez, OL, Jagust, W, Breitner, JC, et al. Incidence and prevalence of dementia in the Cardiovascular Health Study. J Am Geriatr Soc. 2004;52:195-204.Google Scholar
123. Fuhrer, R, Dufouil, C, Dartigues, JF, PAQUID Study. Exploring sex differences in the relationship between depressive symptoms and dementia incidence: prospective results from the PAQUID Study. J Am Geriatr Soc. 2003;51:1055-1063.Google Scholar
124. Garre-Olmo, J, Genis Batlle, D, del Mar Fernandez, M, Marquez Daniel, F, de Eugenio Huelamo, R, Casadevall, T, et al. Incidence and subtypes of early-onset dementia in a geographically defined general population. Neurology. 2010;75:1249-1255.Google Scholar
125. Knopman, DS, Petersen, RC, Edland, SD, Cha, RH, Rocca, WA. The incidence of frontotemporal lobar degeneration in Rochester, Minnesota, 1990 through 1994. Neurology. 2004;62:506-508.Google Scholar
126. Kukull, WA, Higdon, R, Bowen, JD, McCormick, WC, Teri, L, Schellenberg, GD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol. 2002;59:1737-1746.Google Scholar
127. Larrieu, S, Letenneur, L, Helmer, C, Dartigues, JF, Barberger-Gateau, P. Nutritional factors and risk of incident dementia in the PAQUID longitudinal cohort. J Nutr Health Aging. 2004;8:150-154.Google Scholar
128. Larrieu, S, Letenneur, L, Orgogozo, JM, Fabrigoule, C, Amieva, H, Le Carret, N, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002;59:1594-1599.Google Scholar
129. Lee, JY, Chang, SM, Jang, HS, Chang, JS, Suh, GH, Jung, HY, et al. Illiteracy and the incidence of Alzheimer’s disease in the Yonchon County survey, Korea. Int Psychogeriatr. 2008;20:976-985.Google Scholar
130. Lopez-Pousa, S, Vilalta-Franch, J, Llinas-Regla, J, Garre-Olmo, J, Román, GC. Incidence of dementia in a rural community in Spain: the Girona cohort study. Neuroepidemiology. 2004;23:170-177.Google Scholar
131. Matsui, Y, Tanizaki, Y, Arima, H, Yonemoto, K, Doi, Y, Ninomiya, T, et al. Incidence and survival of dementia in a general population of Japanese elderly: the Hisayama study. J Neurol Neurosurg Psychiatry. 2009;80:366-370.Google Scholar
132. McDowell, I, Xi, G, Lindsay, J, Tierney, M. Mapping the connections between education and dementia. J Clin Exp Neuropsychol. 2007;29:127-141.Google Scholar
133. Meguro, K, Ishii, H, Kasuya, M, Akanuma, K, Meguro, M, Kasai, M, et al. Incidence of dementia and associated risk factors in Japan: The Osaki–Tajiri Project. J Neurol Sci. 2007;260:175-182.Google Scholar
134. Mercy, L, Hodges, JR, Dawson, K, Barker, RA, Brayne, C. Incidence of early-onset dementias in Cambridgeshire, United Kingdom. Neurology. 2008;71:1496-1499.Google Scholar
135. Nitrini, R, Caramelli, P, Herrera, E Jr, Bahia, VS, Caixeta, LF, Radanovic, M, et al. Incidence of dementia in a community-dwelling Brazilian population. Alzheimer Dis Assoc Disord. 2004;18:241-246.Google Scholar
136. Perez, F, Helmer, C, Dartigues, JF, Auriacombe, S, Tison, F. A 15-year population-based cohort study of the incidence of Parkinson’s disease and dementia with Lewy bodies in an elderly French cohort. J Neurol Neurosurg Psychiatry. 2010;81:742-746.Google Scholar
137. Phung, TKT, Waltoft, BL, Kessing, LV, Mortensen, PB, Waldemar, G. Time trend in diagnosing dementia in secondary care. Dement Geriatr Cogn Disord. 2010;29:146-153.Google Scholar
138. Polvikoski, T, Sulkava, R, Rastas, S, Sutela, A, Niinisto, L, Notkola, IL, et al. Incidence of dementia in very elderly individuals: a clinical, neuropathological and molecular genetic study. Neuroepidemiology. 2006;26:76-82.Google Scholar
139. Ravaglia, G, Forti, P, Lucicesare, A, Piscane, N, Rietti, E, Biachin, M, et al. Physical activity and dementia risk in the elderly: findings from a prospective Italian study. Neurology. 2008;70:1786-1794.Google Scholar
140. Ravaglia, G, Forti, P, Maioli, F, Martelli, M, Servadei, L, Brunetti, N, et al. Incidence and etiology of dementia in a large elderly Italian population. Neurology. 2005;64:1525-1530.Google Scholar
141. Ravaglia, G, Forti, P, Maioli, F, Montesi, F, Rietti, E, Pisacane, N, et al. Risk factors for dementia: data from the Conselice study of brain aging. Arch Gerontol Geriatr. 2007;44(Suppl 1):311-320.Google Scholar
142. Ruitenberg, A, Ott, A, van Swieten, JC, Hofman, A, Breteler, MM. Incidence of dementia: does gender make a difference? Neurobiol Aging. 2001;22:575-580.Google Scholar
143. Tang, MX, Cross, P, Andrews, H, Jacobs, DM, Small, S, Bell, K, et al. Incidence of AD in African Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001;56:49-56.Google Scholar
144. Tyas, SL, Tate, RB, Wooldrage, K, Manfreda, J, Strain, LA. Estimating the incidence of dementia: the impact of adjusting for subject attrition using health care utilization data. Ann Epidemiol. 2006;16:477-484.Google Scholar
145. Vermeer, SE, Prins, ND, den Heijer, T, Hofman, A, Koudstaal, PJ, Breteler, MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-1222.Google Scholar
146. Waite, LM, Broe, GA, Grayson, DA, Creasey, H. The incidence of dementia in an Australian community population: the Sydney Older Persons Study. Int J Geriatr Psychiatry. 2001;16:680-689.Google Scholar
147. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders–IV–Text Revision. Washington, DC: American Psychiatric Association; 1994.Google Scholar
148. McKhann, G, Drachman, D, Folstein, M, Katzman, R, Price, D, Stadlan, EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS–ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939-944.Google Scholar
149. Hendrie, HC, Osuntokun, BO, Hall, KS, Ogunniyi, AO, Hui, SL, Unverzagt, FW, et al. Prevalence of Alzheimer’s disease and dementia in two communities: Nigerian Africans and African Americans. Am J Psychiatr. 1995;152:1485-1492.Google Scholar
150. Danila, O, Hirdes, JP, Maxwell, CJ, Marrie, RA, Patten, S, Pringsheim, T, Jetté, N. Prevalence of neurological conditions across the continuum of care based on interRAI assessments. BMC Health Serv Res. 2014;14:29.Google Scholar
151. Hebert, LE, Weuve, J, Scherr, PA, Evans, DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80:1778-1783.Google Scholar
152. Andersen, K, Launer, LJ, Dewey, ME, Letenneur, L, Ott, A, Copeland, JR, et al. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology. 1999;53:1992-1997.Google Scholar
153. Fratiglioni, L, Launer, LJ, Andersen, K, Breteler, MM, Copeland, JR, Dartiques, JF, et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54:S10-S15.Google Scholar
154. Mielke, MM, Vemuri, P, Rocca, WA. Clinical epidemiology of Alzheimer disease: assessing sex and gender differences. Clin Epidemiol. 2014;6:37-48.Google Scholar
155. Chene, G, Beiser, A, Au, R, Preis, SR, Wolf, PA, Dufouil, C, et al. Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. Alzheimers Dement. 2015;11:310-320.Google Scholar
156. World Health Organization. The ICD–10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva: World Health Organization; 1993.Google Scholar
157. Erkinjuntti, T, Ostbye, T, Steenhuis, R, Hachinski, V. The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med. 1997;337:1667-1674.Google Scholar
158. Wilson, RS, Weir, DR, Leurgans, SE, Evans, DA, Hebert, LE, Langa, KM, et al. Sources of variability in estimates of the prevalence of Alzheimer’s disease in the United States. Alzheimers Dement. 2011;7:74-79.Google Scholar
159. McKhann, GM, Knopman, DS, Chertkow, H, Hyman, BT, Jack, CR Jr, Kawas, CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263-269.Google Scholar
160. Dubois, B, Feldman, HH, Jacova, C, Hampel, H, Molinuevo, JL, Blennow, K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG–2 criteria. Lancet Neurol. 2014;13:614-629.Google Scholar
161. Lopez, OL, McDade, E, Riverol, M, Becker, JT. Evolution of the diagnostic criteria for degenerative and cognitive disorders. Curr Opin Neurol. 2011;24:532-541.Google Scholar
162. World Health Organization. Life Expectancy at Birth. Geneva: World Health Organization; 2011.Google Scholar
163. Pringsheim, T, Jetté, N, Frolkis, A, Steeves, TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014:291583-291590.Google Scholar
164. Pringsheim, T, Wiltshire, K, Day, L, Dykeman, J, Steeves, T, Jetté, N. The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov Disord. 2012;27:1083-1091.Google Scholar
165. Norton, S, Matthews, FE, Barnes, D, Yaffe, K, Brayne, C. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13:788-794.CrossRefGoogle ScholarPubMed
166. Schrijvers, E, Verhaaren, B, Koudstaal, P, Hofman, A, Ikram, MA, Breteler, MM. Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology. 2012;78:1456-1463.Google Scholar
167. Matthews, FE, Arthur, A, Barnes, LE, Bond, J, Jagger, C, Robinson, L, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet. 2013;382:1405-1412.Google Scholar
Figure 0

Figure 1 Study flow diagram.

Figure 1

Table 1 Studies Reporting on the Prevalence of Alzheimer’s Disease

Figure 2

Table 2 Studies Reporting on the Incidence Rate of Alzheimer’s Disease

Figure 3

Table 3 Studies Reporting on the Incidence Proportion of Alzheimer’s Disease

Figure 4

Figure 2 Pooled point prevalence of Alzheimer’s Disease.

Figure 5

Figure 3 Pooled period prevalence of Alzheimer’s disease.

Figure 6

Figure 4 Pooled incidence proportion of Alzheimer’s disease.

Figure 7

Figure 5 Pooled incidence rate of Alzheimer’s disease.

Figure 8

Table 4 Quality assessment scores of Alzheimer’s Disease incidence and prevalence studies

Supplementary material: File

Fiest supplementary material S1

Appendix

Download Fiest supplementary material S1(File)
File 28.7 KB
Supplementary material: File

Fiest supplementary material S2

Appendix

Download Fiest supplementary material S2(File)
File 18.2 KB